

Stimulation:
w/o
TGFα (100ng/ml)
TNFα (100ng/ml)
Iressa
Cetuximab
Matuzumab
WB: pEGFR (Tyr1068)
WB: pERK1/2

Fig. 1



Stimulation:
w/o
TGFα (100ng/ml)
TNFα (100ng/ml)
Iressa
Cetuximab
Matuzumab
WB: COX2

Fig. 2



Keartinocytes +TGFα (100 ng/ml)
Iressa
Cetuximab
Matuzumab
IL-8 [pg/ml]
EGFR inhibitor [nM]
Keartinocytes +TNFα (100 ng/ml)
Keartinocytes w/o
Keartinocytes +TGFα (10 ng/ml)
EGFR inhibitor[nM]

Fig. 3



Keartinocytes w/o
Keartinocytes + TGFα (10 ng/ml)
Keartinocytes + TGFα (100 ng/ml)
Keartinocytes + TNFα (100 ng/ml)
Iressa
Cetuximab
Matuzumab
RANTES [pg/ml]
EGFR inhibitor [nM]
0,01
0,1
1
10
100
1000
10000

Fig. 4



Keartinocytes w/o
Keartinocytes + TGFα (10 ng/ml)
Keartinocytes + TNFα (100 ng/ml)
Keartinocytes + TGFα (10 ng/ml)
Iressa
Cetuximab
Matuzumab
IP-10 [pg/ml]
EGFR inhibitor [nM]
EGFR inhibitor[nM]

Fig. 5



A431 w/o
A431 + TGFα (10 ng/ml)
A431 + TGFα (100 ng/ml)
A431 + TNFα (100 ng/ml)
Iressa
Cetuximab
Matuzumab
IL-8 [pg/ml]
EGFR inhibitor [nM]
EGFR inhibitor[nM]

Fig. 6



A431 w/o
A431 + TGFα (10 ng/ml)
A431 + TGFα (100 ng/ml)
A431 + TNFα (100 ng/ml)
Iressa
Cetuximab
Matuzumab
RANTES [pg/ml]
EGFR inhibitor [nM]

Fig. 7




A431 w/o
A431 + TGFα (100 ng/ml)
A431 + TGFα (10ng/ml)
A431 + TNFα (100 ng/ml)
Iressa
Cetuximab
Matuzumab
IP-10 [pg/ml]
EGFR inhibitor [nM]
EGFR inhibitor[nM]

Fig. 8


IL-8 levels in response to Matuzumab
A431
PC-3
DiFi
HT-29
Secretion of IL-8 [% of control]
120
100
80
60
40
20
0
0,01
0,1
1
10
100
EMD72k [µg/ml]



IL-8 levels in response to Cetuximab
A431
PC-3
DiFi
HT-29
Secretion of IL-8 [% of control]
120
100
80
60
40
20
0
0,01
0,1
1
10
100
C225 [µg/ml]

Fig. 9